Return of the King, Pharmaceuticals that is
King Pharmaceuticals, Inc. (Public, NYSE:KG) stock has finally inched up 4% since Tuesday (10/16) after falling 49% since this summer. Shares of the King are in the $10 range which has made its P/E more reasonable with a value of 8.5. Friday KG announced they are eliminating 20% of their workforce and we think its the right move for shareholders.
Yesterday (10/19) Citi Investment Research analyst Andrew Swanson upgraded King to "Hold" from "Sell", saying the job cuts were the right move. Swanson expects King's earnings to keep falling for the next few quarters, but said the stock price, which is trading around two-year lows, now reflects that risk.
King Pharma's game plan is to devote more attention to its painkilling drugs, and because it will need fewer sales representatives to sell those drugs, it could cut its 1,200-person sales force in half. "The company can now focus on its pain portfolio, where it is looking to reinvigorate soft prescription trends for Avinza and is awaiting Phase III data for Remoxy," said Swanson.
Positive trial data could lift the stock, he said, but painkiller Remoxy is the only promising drug in King's pipeline and it will not reach the market for at least a year. Swanson kept a price target of $12 per share.
The last three years for King included a rise to the top and then right back down again. So now can they finally get their act together?
Last month, a federal appeals court ruled to overturn the patent supporting Altace, in a case brought against King and distribution partner Sanofi-Aventis by Indian generic drug maker Lupin Ltd. King appealed the ruling, but said it will focus on other drugs.
King stock has lost nearly half its value over the last three months as investors worried about the Altace ruling, along with challenges to the patent on King's muscle relaxant Skelaxin and greater generic competition for its hemostatic product, Thrombin-JMI. The three drugs are King's top sellers. The Masters like the money KG has been pulling in the past two years and we're starting to like the odds on King:
King Pharma's Financials (In millions of USD)
If King Pharma can continue to get its act together, there's no reason this stock can't return to the $20 range.
Article by Ted Gottsegen
Contributor at TheStockMasters.com
Disclaimer: The Author does not hold any positions or shares in the securities mentioned in this publication nor does he stuff his shorts.
Our Original newsletter that has enlightened our subscribers for over a year. It contains What to Buy, What to Sell, and Market Commentary. We have a 17.5% return since October 2006 and the average wait for a return is only 3.61 months and we have the track record to prove it (click here to view Master Picks track record). We've had great feedback, and in turn have already created a unique following of thousands of Stockmasters. Our asking price is only $45 for a 12 month subscription.
Best of the Blogs
Scanning and identifying the best blog entries every hour
- Weekend Reading: The End Of 'Choppiness' | ZeroHedge
- Europe’s Impossible Refugee Math: Brexit Was Mathematical Certainty Eventually | Financial Sense
- The Best Investment Ever? | ZeroHedge
- The War In Afghanistan Is A Good Thing (If You're A Drug-Dealer) | ZeroHedge
- Does Everyone Hate Ted Cruz: The Answer In One Diagram | ZeroHedge
- France Escalates - Sends Aircraft Carrier To Fight ISIS | ZeroHedge
- The Fuel That May Halt The Electric Car Revolution | Financial Sense
The most relevant financial news and articles from the Internets
- THE DISRUPTION OF MOBILE VIDEO: How... | Business Insider
- The $6 trillion opportunity in the IoT | Business Insider
- This beginner drone can compete with models that are much more expensive | Business Insider
- In a Twitter rant, billionaire Mark Cuban tells Clinton how to become... | Business Insider
- This Cleveland ice-cream store captures the essence of Donald Trump in an all-new... | Business Insider
- 8 things to devour in Iceland | Business Insider
- Is Lending Club's crash a preview of fintech's... | Business Insider